ProQR Therapeutics

Yahoo Finance • last year

ProQR Announces Third Quarter 2023 Operating and Financial Results

Continued advancement of platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Further strengthened leading intellectual property (IP) position... Full story

Yahoo Finance • last year

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has further strength... Full story

Yahoo Finance • last year

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA ed... Full story

Yahoo Finance • last year

ProQR Therapeutics Provides Update on Ophthalmic Assets

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previ... Full story

Yahoo Finance • last year

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA edi... Full story

Yahoo Finance • 2 years ago

ProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From Profitability

We feel now is a pretty good time to analyse ProQR Therapeutics N.V.'s (NASDAQ:PRQR) business as it appears the company may be on the cusp of a considerable accomplishment. ProQR Therapeutics N.V., a biotechnology company, focuses on the d... Full story

Yahoo Finance • 2 years ago

ProQR Announces First Quarter 2023 Operating and Financial Results

Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic are... Full story

Yahoo Finance • 2 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA edi... Full story

Yahoo Finance • 2 years ago

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA ed... Full story

Yahoo Finance • 2 years ago

Why Shares of ProQR Therapeutics Dropped on Wednesday

Shares of ProQR Therapeutics (NASDAQ: PRQR) were down 31% Wednesday morning after the company reported 2022 full-year earnings and updated the status of its pipeline. ProQR is a clinical-stage biopharmaceutical company that focuses on RNA-... Full story

Yahoo Finance • 2 years ago

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025Axiomer activity demonstrated acros... Full story

Yahoo Finance • 2 years ago

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully de... Full story

Yahoo Finance • 2 years ago

ProQR to Present at Upcoming Scientific and Industry Conferences

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced several presentations... Full story

Yahoo Finance • 2 years ago

ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will h... Full story

Yahoo Finance • 2 years ago

Lilly and ProQR to Expand RNA Editing Collaboration

INDIANAPOLIS; LEIDEN, Netherlands; and CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and collaboration a... Full story

Yahoo Finance • 2 years ago

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced... Full story

Yahoo Finance • 2 years ago

ProQR Announces Third Quarter 2022 Operating and Financial Results

Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023Management Team appoi... Full story

Yahoo Finance • 2 years ago

ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- LEIDEN, Netherlands & CAMBRIDGE, Mass., November 3, 2022 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through t... Full story

Yahoo Finance • 2 years ago

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/earl... Full story

Yahoo Finance • 2 years ago

ProQR Announces Second Quarter 2022 Operating and Financial Results

ProQR Therapeutics N.V. ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022 Company plans to discuss findings... Full story